Jean-Jacques Garaud, head of Roche Pharma Research and Early Development and member of the Enlarged Corporate Executive Committee, left the company effective 30 June 2012. Effective 1 July 2012, Mike Burgess, currently Global Head Oncology and Large Molecule Research, became acting head of Roche Pharma Research and Early Development and a member of the Enlarged Corporate Executive Committee, reporting to Group CEO Severin Schwan.
With regard to the management change Schwan said, “Jean-Jacques Garaud has played a key role in helping to strengthen Roche’s R&D pipeline. We would like to thank him for his valuable contributions to the Group’s success.”

Source: F. Hoffmann-La Roche Ltd